Skip to main content
. 2021 Apr 27;6(11):4209–4242. doi: 10.1016/j.bioactmat.2021.04.021

Fig. 18.

Fig. 18

(a) The fabrication process of FPMF nanocomposites and the mechanism of anti-tumor immune responses by FPMF@CpG ODN nanocomposites by combining immunotherapy, CDT, and PTT for anticancer therapeutic applications. (b) Fluorescence microscopy images of DCFH-DA labeled 4T1, HeLa, MCF-7 and L02 cells incubated with FPMF NPs for 6 h at the Fe concentration of 80 mg/mL. (c) Viabilities of 4T1 and L02 cells treated with different times at the same Fe concentration of 80 mg/mL. (d) The volume of tumors in tumor-bearing mice during different treatments. (Group: A: PBS, B: PBS + laser, C: MoS2-FA, D: MoS2-FA + laser, E: FePt-FA, F: FePt-FA + laser, G: FePt/MoS2-FA, and H: FePt/MoS2-FA + laser, n = 5). Reprinted with permission from Ref. [374]. Copyright 2019, Nanoscale.